FORM 4 [X] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Wegman Toby		 2. Issuer Name and Ticker or Trading Symbol

BIOSPECIFICS TECHNOLOGIES CORP [ BSTC ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    __X__ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle)

C/O BIOSPECIFICS TECHNOLOGIES CORP., 2 RIGHTER PKWY, DE CORP CENTER II		 3. Date of Earliest Transaction (MM/DD/YYYY)

12/2/2020
(Street)

WILMINGTON, DE 19803
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
 6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, $0.001 par value 12/2/2020  D  1890 D (1)1726 D  
Common Stock, $0.001 par value 12/2/2020  D  1726 D (2)0 D  
Common Stock, $0.001 par value 12/2/2020  D  935073 D (3)0 I See footnote (4)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		8. Price of Derivative Security
(Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
(1) Upon the consummation of the merger (the "Merger") contemplated by that certain Agreement and Plan of Merger, by and among BioSpecifics Technologies Corp., Endo International plc, and Beta Acquisition Corp., dated October 19, 2020 (the "Merger Agreement"), 1,890 shares of common stock were exchanged for a cash payment of $167,265.00, representing the product obtained by multiplying the offer price ($88.50) by the number of shares owned by the reporting person.
(2) Upon the consummation of the Merger, pursuant to the Merger Agreement, 1,726 outstanding restricted stock units ("RSUs") were cancelled in exchange for a cash payment of $152,751.00, representing the product obtained by multiplying (x) the aggregate number of shares of common stock underlying the RSUs, by (y) the offer price ($88.50).
(3) Upon the consummation of the Merger, 935,073 shares of common stock held by the MARITAL TRUST U/W/O EDWIN H WEGMAN DATED 08/10/06 (the "Trust") were exchanged for a cash payment of $82,753,960.50, representing the product obtained by multiplying the offer price ($88.50) by the number of shares owned by the Trust.
(4) These shares are held in trust on behalf of the reporting person. The reporting person is the co-trustee of the Trust. The reporting person disclaims beneficial ownership of the shares held by the Trust except to the extent of the reporting person's pecuniary interest therein.
Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Wegman Toby
C/O BIOSPECIFICS TECHNOLOGIES CORP.
2 RIGHTER PKWY, DE CORP CENTER II
WILMINGTON, DE 19803		XX
Signatures
/s/ Toby Wegman, by Carl A. Valenstein, attorney-in-fact12/2/2020
**Signature of Reporting PersonDate
BioSpecifics Technologies (NASDAQ:BSTC)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more BioSpecifics Technologies Charts.
BioSpecifics Technologies (NASDAQ:BSTC)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more BioSpecifics Technologies Charts.